Thyme Care Raises $97 Million Series D to Drive AI-Powered Oncology Care at $1B Valuation

Thyme Care has raised $97 million in a Series D funding round, bringing its total capital raised to $275 million and pushing the company's valuation above $1 billion15.

Major strategic investors in this round include CVS Health Ventures, Foresite Capital, a16z Bio + Health, Concord Health Partners, Town Hall Ventures, AlleyCorp, Frist Cressey Ventures, as well as new investors such as Morgan Health (JPMorgan Chase), Humana, Texas Oncology, and Memorial Hermann Health System26.

The company has achieved profitability, manages over $5 billion in oncology spend, and now offers access to cancer care services for more than 8 million people nationwide through new Medicare, commercial, and employer contracts2.

Thyme Care’s core offering is an AI-driven care navigation platform designed to eliminate barriers for cancer patients by supporting care teams and integrating stakeholders, delivering timely, personalized support25.

The funding will accelerate national expansion, scale the company’s AI-powered infrastructure, and deepen partnerships to create a more integrated oncology ecosystem focused on value, accountability, and improved patient experience26.

Thyme Care collaborates with oncology practices, health systems, employers, and payers to provide value-based, collaborative care models, aiming to reduce costs and improve outcomes for cancer patients6.

Sources:

1. https://sacra.com/c/thyme-care-inc

2. https://www.moomoo.com/news/post/58972158/97m-series-d-backed-by-strategic-investors-across-the-oncology

5. https://techfundingnews.com/thyme-care-secures-97m-at-1b-valuation-to-scale-ai-powered-affordable-cancer-care/

6. https://www.echohealthventures.com/news/97m-series-d-backed-by-strategic-investors-across-the-oncology-ecosystem-positions-thyme-care-to-break-through-cancer-cares-biggest-bottlenecks/